June's Top Dividend Aristocrat Fat Pitches: Blue-Chip Bargains You Can't MissSeeking Alpha • 06/07/25
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?Zacks Investment Research • 06/06/25
Why Novo Nordisk (NVO) is a Top Dividend Stock for Your PortfolioZacks Investment Research • 06/02/25
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli LillyInvestors Business Daily • 05/29/25
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on trackWSJ • 05/29/25
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?The Motley Fool • 05/28/25
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?Zacks Investment Research • 05/27/25
Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?WSJ • 05/27/25
Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditionsWSJ • 05/26/25
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesZacks Investment Research • 05/23/25
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effectPRNewsWire • 05/22/25
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugsCNBC • 05/21/25